pharmaphorum July 22, 2024
Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life-threatening mosquito-borne disease.
The French biotech is the first company to bring a chikungunya vaccine to market, getting FDA approval for its Ixchiq (VLA1553) shot in November 2023 and in Europe and Canada in June, for adults at risk of the infection.
The new funding will go towards running clinical trials in vulnerable groups, such as children and pregnant women, and to help Valneva’s technology transfer efforts to allow the vaccine to be produced in low- and middle-income countries (LMICs) in Asia.
Chikungunya is an emerging global health threat with at least five...
Today's Sponsors
Today's Sponsor